CMS Grants Pass-Through Status to Lantheus' PYLARIFY TruVu, Boosting Prostate Cancer Imaging Access
Event summary
- CMS granted Transitional Pass-Through (TPT) payment status for PYLARIFY TruVu, effective October 1, 2026.
- PYLARIFY TruVu received a permanent HCPCS code, facilitating billing and reimbursement.
- Over 900,000 patients have received PSMA PET scans with PYLARIFY since its FDA approval in May 2021.
- PYLARIFY TruVu aims to improve manufacturing efficiency and expand geographic reach.
The big picture
The CMS approval for PYLARIFY TruVu underscores the growing importance of advanced diagnostic tools in prostate cancer management. With prostate cancer incidence rates rising, the ability to enhance imaging capabilities through improved manufacturing and broader access is a strategic advantage. Lantheus' move positions it to capitalize on the increasing demand for precise diagnostic solutions in oncology.
What we're watching
- Market Adoption
- How quickly healthcare providers will adopt PYLARIFY TruVu following the TPT status and HCPCS code assignment.
- Supply Chain
- Whether Lantheus can successfully transition its manufacturing network to support PYLARIFY TruVu without disruptions.
- Competitive Dynamics
- The pace at which PYLARIFY TruVu can capture market share in the PSMA PET imaging space.
Related topics